Enzo Biochem Appoints Four Executives at Enzo Life Sciences as Unit Adds Products and Platforms to More Aggressively Expand in Pharmaceutical and Clinical Markets
Chart for Enzo Biochem, Inc. Common Stock
Press Release Source: Enzo Biochem Inc. On Monday August 22, 2011, 10:00 am EDT
NEW YORK--(BUSINESS WIRE)-- Enzo Biochem Inc. (NYSE:ENZ - News) announced today that it has added four highly experienced executives at its Enzo Life Sciences subsidiary to focus on rapidly evolving new pharmaceutical and clinical applications.
The officers, all filling newly created positions, are Bruce Taillon, PhD, as head of global technology business development, John D’Errico, PhD, to lead the commercial merchandising operations, Kara Cannon, as head of global marketing and Paul Munger, PhD, to lead Global Manufacturing.
Over the past two years, Enzo has been engaged in enhancing the Life Sciences subsidiary’s operating performance through added capabilities, greater integration and a more focused product mix. These efforts are all aimed at significantly expanding Enzo’s presence and marketing beyond the traditional academic and research laboratory core to greater penetrate the pharmaceutical and clinical customer base with new and cutting edge platform technologies.
“Enzo Life Sciences has developed numerous new products to meet the demands of these exciting growth markets and our investment in people—which we are announcing today—is a manifestation of our commitment to this exciting strategy. All four individuals are highly experienced, with technical expertise and impressive professional and commercial accomplishments; we are confident they will all make notable contributions to our Company’s growth,” says Barry Weiner, Enzo Biochem President.
Among the additions to Enzo Life Sciences’ offerings is a line of specific products and assays aimed at, among other areas, epigenetics, a burgeoning new approach to studying genetic variations in treatments and drug discoveries among large and small pharma.
Enzo Life Sciences’ emphasis is increasingly on developing platforms and products to meet the expanding needs of new and revolutionary pharmacological and genetic treatments, which often require extensive pre-clinical testing. In addition, these added capabilities will materially enhance the broader esoteric diagnostic direction at Enzo Clinical Labs, another subsidiary of Enzo Biochem, which is itself focused on greater national recognition and expanding the use of its higher value molecular testing capabilities.
The new Enzo Life Science appointments include:
Bruce Taillon, PhD, as head of global technology business development. He previously was associated with Roche Diagnostics’ 454 Life Sciences Division, where he was responsible for world-wide business development efforts centered around the company’s next generation nucleic acid sequencing platform and its potential use in diagnostic assays. He also has experience in leading R&D teams focused in the areas of genomics, proteomics and drug development.
John D’Errico, PhD, He will lead the Company’s commercial merchandising operations. Dr. D’Errico joins Enzo from VWR Scientific, where he managed that company’s life sciences product portfolio. He also brings extensive product management and M&A expertise from Harvard Biosciences, where he headed business development efforts at Genomic Solutions, a Life Science tools company.
Kara Cannon. Ms. Cannon was appointed head of Enzo Life Science’s global marketing, joining the Company after 10 years at Pall Corporation, where she held executive positions in the areas of diagnostics, biotechnology and biosciences. She has had extensive experience in the marketing and selling of innovative platforms for the diagnostics markets as well as the development and execution of strategic plans for the growth and sustainability of diagnostic-related businesses.
Paul Munger, PhD, Dr. Munger will lead Enzo Life Sciences’ Global Manufacturing Operations. He previously held an executive position at Pierce Chemical, now a division of Thermo Fisher, as well as a senior manufacturing management role at Transgenomic, Inc, where he was responsible for scaling up drug intermediate candidates that led to substantial cost reductions while raising quality and reducing turnaround time. Most recently Paul led the US-based manufacturing of regulated diagnostic kits for Idexx Labs.
surf's up......crikey
